What is KLOW? The peptide blend, explained

In late August 2026, a poster on the r/peptides community described a small, minimally displaced avulsion fracture at the top of the heel bone plus an ankle sprain, then asked whether anyone had used a peptide blend called KLOW during a similar recovery^[1]. It is a reasonable question to ask strangers online, and a hard one for anyone else to answer honestly. KLOW is not a single drug. It is a grey market mixture of four separate peptides, none of them approved by the FDA or the EMA for healing bone or soft tissue, and none of them tested together as a combination in a single published study.

What KLOW is actually made of

KLOW is shorthand for four peptides usually mixed into the same vial: BPC-157, TB-500, GHK-Cu, and KPV. BPC-157 is a synthetic fragment of a protein first isolated from human gastric juice, studied almost entirely in rats for tendon, ligament, and gut repair^[4]. TB-500 is the trade name most often applied to thymosin beta-4, a naturally occurring protein that regulates cell movement and wound repair in animal models^[5]. GHK-Cu is a copper-binding tripeptide long used in skincare for its effect on collagen production^[6]. KPV is a three-amino-acid fragment of alpha-MSH studied mainly for calming gut inflammation in mice^[7]. Two of the four, BPC-157 and TB-500, have full reference pages on this site covering what is and is not known about each one, along with the legal status behind them.

What the evidence for each ingredient actually shows

The honest answer is thin, and thin in a specific way. The animal literature on BPC-157 is large. A 2025 systematic review of BPC-157 in orthopaedic sports medicine found dozens of rodent studies reporting faster tendon and ligament healing, and essentially no completed human trials confirming the effect carries over to people^[3]. TB-500 has a similar shape. The preclinical case for thymosin beta-4 speeding tissue repair is well established in cell and animal work, but the only peer-reviewed human trial data sits in an eye drop formulation for a corneal condition, not an injectable product for tendons, ligaments, or bone^[5]. GHK-Cu has more human data than the other three, but almost all of it comes from topical cosmetic trials on skin, not from injectable use in a musculoskeletal injury^[6]. KPV's anti-inflammatory evidence is built on mouse models of bowel disease, not orthopaedic injury in any species^[7]. None of the four has been tested as a combined injectable blend, in an animal or a person, for a fracture or a sprain specifically.

Nothing in KLOW is an approved medicine

The FDA does not recognize KLOW as a product, and it has taken a specific position on one of the peptides inside it. BPC-157 sits in Category 2 of the FDA's list of bulk drug substances for compounding, the category the agency uses for substances it has determined are not eligible for compounding pharmacies to prepare^[2]. That means a licensed US pharmacy cannot lawfully compound it, which is part of why the supply that reaches online forums and vendor sites moves through unregulated channels with no routine identity or purity testing. The EMA and the MHRA have not authorized any of the four peptides in KLOW for any indication. What is sold online as KLOW is a research chemical mixture, not a medicine, regardless of how a vendor markets it.

A real fracture changes the calculation

A minor avulsion fracture and an ankle sprain are not abstract problems. They have an established, evidence-based recovery pathway: appropriate offloading or immobilization, imaging follow-up to confirm the bone is uniting the way it should, and a clinician tracking progress and watching for delayed or non-union. None of that pathway involves an unregulated injectable peptide blend, and there is no human evidence that any of KLOW's four components speeds up bone or ligament healing. The larger risk is not that KLOW does nothing. It is what self-treating with it can displace. Injecting an unregulated, unpurified compound near a healing injury adds an infection risk at exactly the site that most needs to stay clean, and treating a supplement as a substitute for a scheduled orthopedic follow-up can let a slow-healing fracture go unmonitored until it is a bigger problem.

Where this leaves someone healing right now

For someone who fractured a bone and sprained an ankle a few days ago and is reading community threads for encouragement, the honest starting point is that nobody, including people who have used KLOW themselves, can tell that person whether it will change their healing. The literature has not answered that question for any single ingredient, let alone the four-peptide combination. What is well established is that the treating clinician, ideally the one who read the imaging, is the person who should hear about anything being considered as an addition to recovery, including a peptide blend recommended by a stranger online. See the BPC-157 regulation section and the TB-500 regulation section for the country-by-country legal picture on the two components with the deepest published literature.